$277 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 6 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 28.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
HRTX | Buy | HERON THERAPEUTICS INC | $129,824,000 | +59.9% | 8,654,914 | +39.7% | 46.92% | +8.4% |
LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $102,697,000 | +83.6% | 3,440,419 | +7.8% | 37.12% | +24.4% |
RXDX | IGNYTA INC | $34,166,000 | +62.3% | 3,972,800 | 0.0% | 12.35% | +10.0% | |
BMRN | BIOMARIN PHARMACEUTICAL INC | $7,919,000 | +6.0% | 90,215 | 0.0% | 2.86% | -28.2% | |
CYCC | Buy | CYCLACEL PHARMACEUTICALS INC | $2,060,000 | +8.2% | 559,900 | +55.6% | 0.74% | -26.6% |
LIFE | Exit | ATYR PHARMA INC | $0 | – | -279,425 | -100.0% | -0.32% | – |
Exit | OPKO HEALTH INCdebt 3.0% 2/1/33 | $0 | – | -14,000,000 | -100.0% | -10.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
4 | 2024-02-02 |
4 | 2023-12-18 |
13F-HR | 2023-11-14 |
4 | 2023-10-13 |
13F-HR | 2023-08-14 |
3 | 2023-06-01 |
4 | 2023-06-01 |
4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.